Cargando…

85. Efficacy of Sulbactam-Durlobactam (SUL-DUR) Compared to Colistin (COL) against Acinetobacter baumannii-calcoaceticus Complex (ABC) Monomicrobial and Polymicrobial Infections in a Phase 3 Trial

BACKGROUND: Recently, a global, active-controlled Phase 3 trial evaluated the efficacy and safety of SUL-DUR vs. COL for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections, including multidrug resistant strains. Both arms were dosed on a background of imipenem/cilastatin (I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Alita, McLeod, Sarah, Shapiro, Adam B, Rana, Khurram, Altarac, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679224/ http://dx.doi.org/10.1093/ofid/ofad500.001

Ejemplares similares

1254. In vitro activity of sulbactam-durlobactam against recent global clinical Acinetobacter baumannii-calcoaceticus complex isolates
por: McLeod, Sarah, et al.
Publicado: (2020)

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections
por: Bhavnani, Sujata M, et al.
Publicado: (2022)

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021
por: Karlowsky, James A., et al.
Publicado: (2022)

2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function
por: Larson, Kajal, et al.
Publicado: (2023)

2526. Ex Vivo Assessment of Sulbactam-Durlobactam (SUL-DUR) Clearance during Continuous Renal Replacement Therapy (CRRT)
por: Abouelhassan, Yasmeen, et al.
Publicado: (2023)

694. In vitro Antibacterial Activity of Sulbactam–Durlobactam (ETX2514SUL) Against 121 Recent Acinetobacter baumannii Isolated from Patients in India
por: Miller, Alita, et al.
Publicado: (2019)

709. In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam–Durlobactam (ETX2514SUL) Against Pathogenic Burkholderia Species
por: O’Donnell, John, et al.
Publicado: (2019)

518. Characterization of colistin-resistant (COL-R) Acinetobacter baumannii calcoaceticus complex (ABC) isolates from a recent, global Phase 3 trial (ATTACK)
por: Moussa, Samir, et al.
Publicado: (2022)

Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii
por: Moussa, Samir H., et al.
Publicado: (2023)

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam
por: Shapiro, Adam B., et al.
Publicado: (2021)

Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species
por: Papp-Wallace, Krisztina M, et al.
Publicado: (2023)

2138. In Vitro Susceptibility of Recent Clinical Isolates of P. aeruginosa and Enterobacterales to Imipenem or Meropenem Alone or in Combination with Sulbactam-Durlobactam
por: McLeod, Sarah, et al.
Publicado: (2023)

The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex
por: O’Donnell, John P, et al.
Publicado: (2023)

1293. Sulbactam-durlobactam is active against recent, multi-drug resistant Acinetobacter baumannii clinical isolates from the Middle East
por: Miller, Alita, et al.
Publicado: (2020)

2517. Activity of Sulbactam-durlobactam, Antibacterial Combinations, and Comparators Against a Challenge Set of 66 Acinetobacter baumannii-calcoaceticus Species Complex Isolates
por: Huband, Michael D, et al.
Publicado: (2023)

Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review
por: Principe, Luigi, et al.
Publicado: (2022)

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
por: Sagan, Olexiy, et al.
Publicado: (2020)

1642. A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against Multidrug-Resistant (MDR) Mycobacterium abscessus (Mab)
por: Dousa, Khalid M, et al.
Publicado: (2020)

Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections
por: Watkins, Richard R, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects
por: O’Donnell, John, et al.
Publicado: (2019)

In Vivo Emergence of Pandrug-Resistant Acinetobacter baumannii Strain: Comprehensive Resistance Characterization and Compassionate Use of Sulbactam-Durlobactam
por: VanNatta, Mollie, et al.
Publicado: (2023)

An intestinal Candida albicans model for monomicrobial and polymicrobial biofilms and effects of hydrolases and the Bgl2 ligand
por: Masfufatun, Masfufatun, et al.
Publicado: (2022)

Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece
por: Petropoulou, Dimitra, et al.
Publicado: (2022)

656. Sulbactam-Durlobactam MIC Determination: Comparative Evaluation of the New ETEST(®) SUD to the CLSI 2021 Broth Microdilution Method
por: Sauvonnet, Veronique, et al.
Publicado: (2021)

In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales
por: Fouad, Aliaa, et al.
Publicado: (2023)

Comparison of the systemic inflammatory response syndrome between monomicrobial and polymicrobial Pseudomonas aeruginosa nosocomial bloodstream infections
por: Marra, Alexandre R, et al.
Publicado: (2005)

Development and antimicrobial susceptibility studies of in vitro monomicrobial and polymicrobial biofilm models with Aspergillus fumigatus and Pseudomonas aeruginosa
por: Manavathu, Elias K, et al.
Publicado: (2014)

In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy
por: Segatore, Bernardetta, et al.
Publicado: (2022)

2121. In vitro Synergy of the Combination of Sulbactam-Durlobactam and Cefepime at Clinically Relevant Concentrations Against A. baumannii, P. aeruginosa, and Enterobacterales
por: Fouad, Aliaa, et al.
Publicado: (2023)

Polymicrobial and Monomicrobial Infections after Spinal Surgery: A Retrospective Study to Determine which Infection is more Severe
por: Liu, Shaoqiang, et al.
Publicado: (2017)

Susceptibility of monomicrobial or polymicrobial biofilms derived from infected diabetic foot ulcers to topical or systemic antibiotics in vitro
por: Price, Bianca L., et al.
Publicado: (2020)

Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex
por: Ye, Jung-Jr, et al.
Publicado: (2016)

Antimicrobial Susceptibility among Colistin, Sulbactam, and Fosfomycin and a Synergism Study of Colistin in Combination with Sulbactam or Fosfomycin against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii
por: Leelasupasri, Sombat, et al.
Publicado: (2018)

Salvage therapy with sulbactam/durlobactam against cefiderocol-resistant Acinetobacter baumannii in a critically ill burn patient: clinical challenges and molecular characterization
por: Tiseo, Giusy, et al.
Publicado: (2023)

Risk factors and clinical responses of pneumonia patients with colistin-resistant Acinetobacter baumannii-calcoaceticus
por: Aydemir, Hande, et al.
Publicado: (2019)

2515. Evaluation of the Equivalency of the Oxoid Sulbactam-Durlobactam (10/10µg) Antimicrobial Disc to the CLSI M07 Broth Microdilution Frozen Reference Method
por: Hajek, Katie L, et al.
Publicado: (2023)

2285. Emergence of perioperative antibiotic non-susceptible pathogens causing prosthetic joint infections in monomicrobial Gram-negative and polymicrobial infections.
por: Coyle, Meredith M, et al.
Publicado: (2019)

Polymicrobial and monomicrobial necrotizing soft tissue infections: comparison of clinical, laboratory, radiological, and pathological hallmarks and prognosis. A retrospective analysis
por: Naamany, Eviatar, et al.
Publicado: (2021)

Diagnostic performance and clinical impact of blood metagenomic next-generation sequencing in ICU patients suspected monomicrobial and polymicrobial bloodstream infections
por: Liu, Qilong, et al.
Publicado: (2023)

1670 Comparative Metagenomics of Polymicrobial Surface Organisms and Their Invasive Monomicrobial Analogs Indicates the Rate of Genetic Alterations in the Infectious Organisms not Influenced by the Local Microbiome
por: Nielsen, Lindsey, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_u3thun7g37tn7025a1qqeoa99a